Peer-reviewed veterinary case report
Mitoquinone stops growth and kills dog mammary tumor cells
By Lee, Ran et al.·Published in International journal of molecular sciences·2024·Department of Livestock, South Korea·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Anticancer Effects of Mitoquinone via Cell Cycle Arrest and Apoptosis in Canine Mammary Gland Tumor Cells.
- Species:
- dog
Plain-English summary
A study found that Mitoquinone (MitoQ), an antioxidant, may help treat female dogs with mammary gland tumors, which can grow quickly and spread. In laboratory tests, MitoQ significantly slowed down the growth and movement of tumor cells and caused cancer cell death. It worked by disrupting the cell cycle and increasing proteins that trigger cell death. These promising results suggest that MitoQ could be a potential treatment option for dogs with mammary cancer, but further research is needed to confirm its effectiveness in real-life cases.
People also search for: dog mammary tumor treatment · MitoQ for canine cancer · female dog breast cancer symptoms
Abstract
Treating female canine mammary gland tumors is crucial owing to their propensity for rapid progression and metastasis, significantly impacting the overall health and well-being of dogs. Mitoquinone (MitoQ), an antioxidant, has shown promise in inhibiting the migration, invasion, and clonogenicity of human breast cancer cells. Thus, we investigated MitoQ's potential anticancer properties against canine mammary gland tumor cells, CMT-U27 and CF41.Mg. MitoQ markedly suppressed the proliferation and migration of both CMT-U27 and CF41.Mg cells and induced apoptotic cell death in a dose-dependent manner. Furthermore, treatment with MitoQ led to increased levels of pro-apoptotic proteins, including cleaved-caspase3, BAX, and phospho-p53. Cell cycle analysis revealed that MitoQ hindered cell progression in the G1 and S phases in CMT-U27 and CF41.Mg cells. These findings were supported using western blot analysis, demonstrating elevated levels of cleaved caspase-3, a hallmark of apoptosis, and decreased expression of cyclin-dependent kinase (CDK) 2 and cyclin D4, pivotal regulators of the cell cycle. In conclusion, MitoQ exhibits in vitro antitumor effects by inducing apoptosis and arresting the cell cycle in canine mammary gland tumors, suggesting its potential as a preventive or therapeutic agent against canine mammary cancer.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/38732133/